Willem Dewilde

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

Unifocal Right-Sided Ablation Treatment for Neurally Mediated Syncope and Functional Sinus Node Dysfunction Under Computed Tomographic Guidance

Philippe Debruyne, Tom Rossenbacker, Christine Collienne et al. · Circulation Arrhythmia and Electrophysiology · 2018 · 106 citations · Full text

Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST)

Willem Dewilde, Jurriën M. ten Berg · American Heart Journal · 2009 · 70 citations

Thrombosis, Percutaneous Coronary Intervention, Cardiovascular Disease +12

Real-world experience with a novel biodegradable polymer sirolimus-eluting stent: twelve-month results of the BIOFLOW-III registry

Johannes Waltenberger, Johannes Brachmann, Jan Van der Heyden et al. · EuroIntervention · 2016 · 38 citations

Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk

Pieter C. Smits, Enrico Frigoli, Pascal Vranckx et al. · Journal of the American College of Cardiology · 2022 · 29 citations · Full text